Winclove Clear is developed to inhibit growth of pathogens in the vagina and bladder, and stimulate the immune system. This is achieved by combining probiotics with the functional ingredient cranberry. Cranberry is well-known for its capacities as a non-antibiotic treatment in case of a rUTI.
The probiotic strains in Winclove Clear have been tested and selected in vitro for their capacity to:
• survive the gastro-intestinal tract
• inhibit pathogens
• adhere to surface of epithelial cells
• form aggregations
• positively stimulate the immune system
(decrease production of IL-6 and IL-8 and
increase production of IL-10)
• strengthen the gut barrier function
• produce lactic acid.
The capacity of the probiotic strains to inhibit the uropathogen E.coli is shown in the figure. E.coli often enters the bladder via the vagina from the rectum and is able to colonize the bladder epithelium. The graph shows that all strains in Winclove Clear are very well capable of inhibiting E.coli.
The effect of the probiotic strains to strengthen the gut epithelial barrier is shown in the second figure. For this, trans epithelial electric resistance (TEER) was measured in a transwell system of a CaCo2 cell line. An increase in the percentage of TEER indicates an improved barrier function. The graph shows that all strains in Winclove Clear are capable to strengthen the barrier function.